Evidence map›Paper›PMID 42162557›Full record

ArticleClinical and experimental immunology2026

Depletion and recovery of IgG following treatment with an anti-FcRn antibody and IdeS in pigtail macaques.

Kara M Rzasa, Joanna Zikos, Toni Penney, Faith R Schiro, Lara A Doyle-Meyers, Pyone P Aye, Ronald S Veazey, James A Hoxie, Nicholas J Maness, Diogo M Magnani and 1 more

Abstract read
In one paragraph

Article in Clinical and experimental immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Kara M RzasaDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.ORCID 0000-0002-5753-7517
Joanna ZikosDepartment of Medicine, UMass Chan Medical School, Worcester, MA, USA.
Toni PenneyDepartment of Microbiology and Immunology, Tulane School of Medicine, Covington, LA, USA.
Faith R SchiroTulane National Biomedical Research Center, Tulane University, New Orleans, LA, USA.
Lara A Doyle-MeyersDepartment of Microbiology and Immunology, Tulane School of Medicine, Covington, LA, USA.
Pyone P AyeTulane National Biomedical Research Center, Tulane University, New Orleans, LA, USA.
Ronald S VeazeyTulane National Biomedical Research Center, Tulane University, New Orleans, LA, USA.
James A HoxieDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Nicholas J ManessDepartment of Microbiology and Immunology, Tulane School of Medicine, Covington, LA, USA.
Diogo M MagnaniDepartment of Medicine, UMass Chan Medical School, Worcester, MA, USA.
Margaret E AckermanDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.ORCID 0000-0002-4253-3476

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Structure-Function Analytics CoreP01AI162242 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2021 to 2025
$22.2M
Viral Testing Core - Maintenance of an SPF Macaque Breeding Colony for AIDS ResearchU42OD010568 · OD · TULANE UNIVERSITY OF LOUISIANA · PI KASI E RUSSELL-LODRIGUE · 2013 to 2026
$21.7M
Nonhuman Primate Reagent ResourceU24AI126683 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2016 to 2026
$20.1M
Impact of tuberculosis on the development and function of the immune system in SIV-infected infantsR01HD099857 · NICHD · TULANE UNIVERSITY OF LOUISIANA · PI KAUSHAL, DEEPAK, WANG, XIAOLEI · 2019 to 2023
$6.9M
ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
Early prevention interventions towards ART-free pediatric HIV remissionR01MH133474 · NIMH · TULANE UNIVERSITY OF LOUISIANA · PI Ronald S. Veazey · 2023 to 2026
$3.0M
Mechanisms and means to improve HIV bnAb activity in vivoR01AI183970 · NIAID · DARTMOUTH COLLEGE · PI Margaret E Ackerman · 2024 to 2026
$2.5M
Molecular characterization and modeling efficient antibody effector functionR01AI186995 · NIAID · DARTMOUTH COLLEGE · PI Margaret E Ackerman · 2025 to 2026
$884k
NIAID NIH HHS P01 AI162242NIAID NIH HHS P01AI162242NIAID NIH HHS R01 AI183970NIAID NIH HHS R01AI183970NIAID NIH HHS R01 AI186995NIAID NIH HHS R01AI186995NIAID NIH HHS U24 AI126683NIAID NIH HHS U24AI126683NICHD NIH HHS R01 HD099857NIGMS NIH HHS R01 GM129325NIH HHS P51 OD011104NIH HHS U42 OD010568NIMH NIH HHS R01 MH133474
6 · The paper itself

Abstract

Antibodies are central players in adaptive immunity, providing protection against a wide array of pathogens through mechanisms such as neutralization, opsonization, recruitment of effector immune cells, complement activation, and engagement. However, in other contexts, these same effector functions can contribute to immunopathology, particularly when antibodies are developed against self-antigens, resulting in autoimmunity. Understanding the role antibodies play in preventing or causing disease is often supported by studies in model systems wherein manipulation of immunoglobulin G (IgG) levels can be used as an experimental tool. Here, we report in simian immunodeficiency virus (SIV) infected pigtail macaques (Macaca nemestrina) the capacity of two orthogonal strategies to systemically deplete IgG: treatment with a primatized neonatal Fc receptor blocking antibody (anti-FcRn) modelled on rozanolixizumab that restricts IgG rescue and recycling, and administration of the IgG protease IdeS that cleaves the Fc domain. Under the conditions evaluated, we observed more rapid and effective, although not necessarily more durable, IgG depletion mediated by IdeS, reducing levels by 74.1-95.1%, compared with a lesser reduction of 31.3-66.9% with anti-FcRn treatment. We observed a similar degree of depletion, comparable kinetics of rebound among SIV antigen-specific fractions as total IgG, but differential balance among IgG subclasses following treatment in some cases. In sum, this study in a non-human primate model describes the efficacy and downstream impacts of new tools to modify humoral immune states, providing insight into the balance between protective and pathological effects of IgG antibodies.

Indexed as

Histocompatibility Antigens Class IImmunoglobulin GReceptors, FcSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsMacaca nemestrinaFc receptor, neonatalHistocompatibility Antigens Class IImmunoglobulin GReceptors, Fcantibody effector functionsFcRn blocking antibodyIgG depletionIgG protease IdeSrozanolixizumab

Identifiers

PMID42162557
PMCPMC13248873

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.